IOVANCE BIOTHERAPEUTICS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net loss ($52.9m) ($92.1m) ($123.6m) ($197.6m) ($259.6m) ($342.3m) ($395.9m) ($444.0m) ($372.2m) ($391.0m)
Net Income (Loss) Attributable to Parent ($52.9m)
($92.1m) -74.05%
($123.6m) -34.23%
($197.6m) -59.86%
($259.6m) -31.40%
($342.3m) -31.85%
($395.9m) -15.67%
($444.0m) -12.16%
($372.2m) +16.18%
($391.0m) -5.05%
Net Income (Loss) Available to Common Stockholders, Basic ($102.3m)
($92.1m) +10.05%
($123.6m) -34.23%
Depreciation, Depletion and Amortization $978k $952k $956k $1.2m $1.1m $3.1m $9.3m $11.6m $12.0m $12.9m $45.0m
Depreciation $1.0m $1.0m $1.0m $1.2m $1.1m $3.1m $9.3m $21.9m
Amortization of Intangible Assets $0 $9.8m $21.2m $23.1m
Amortization of right of use asset $7.0m $7.6m $10.9m $11.8m $11.7m $10.4m $11.4m
Depreciation and amortization of property and equipment $952k $956k $1.2m $1.1m $3.1m $9.3m $11.6m $12.0m $12.9m $45.0m
Deferred Income Tax Expense (Benefit) $0 $0 $0 $0 $0 ($3.5m) ($2.8m) ($2.1m) ($4.3m)
Deferred tax (benefit) expense ($3.5m) ($2.8m) ($2.1m)
Share-based Payment Arrangement, Noncash Expense $18.9m $12.0m $20.0m $24.3m $40.9m $69.8m $84.0m $62.6m $109.6m $61.6m $46.7m
Payment, Tax Withholding, Share-based Payment Arrangement $642k $1.3m $223k $312k $284k $2.6m $2.8m $12.9m $7.1m
Share-based Payment Arrangement, Expense $1.0m $0 $46.7m
Share-based Payment Arrangement, Expensed and Capitalized, Amount $18.9m $12.0m $20k $24.3m $40.9m $69.8m $84.0m $62.6m $109.6m $61.6m $46.7m
Stock-based compensation expense $18.9m $12.0m $20.0m $24.3m $40.9m $69.8m $84.0m $62.6m $109.6m $61.6m $46.7m
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable $149k $69.2m $13.1m ($42.2m)
Trade accounts receivable ($149k) ($69.2m) ($13.1m)
Increase (Decrease) in Inventories $10.1m $39.9m $14.2m ($12.1m)
Inventory Write-down $13.4m
Inventory ($10.1m) ($39.9m) ($14.2m) ($12.1m)
Increase (Decrease) in Accounts Payable ($250k) $369k $1.5m $12.7m ($3.0m) $7.0m $5.9m $4.8m ($7.8m) ($6.7m) ($5.5m)
Acquisition of property and equipment included in accounts payable and accrued expenses $122k ($5.1m) ($7.3m) ($6.0m) $4.1m $7.4m $8.5m
Accrued expenses and other liabilities $3.4m $4.6m $3.2m $6.7m $24.1m $20.7m ($4.7m) $19.8m $8.6m $28.6m
Prepaid expenses, other assets and long-term assets ($2.8m) ($875k) ($2.1m) ($3.3m) ($6.7m) $2.8m ($2.1m) ($10.1m) ($2.1m) ($8.0m)
Net Cash Provided by (Used in) Operating Activities ($32.7m)
($78.7m) -140.94%
($101.2m) -28.64%
($158.9m) -56.93%
($205.1m) -29.11%
($227.9m) -11.12%
($292.8m) -28.44%
($361.8m) -23.59%
($353.0m) +2.44%
($302.4m) +14.33%
($264.2m) +12.64%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $1.5m $1.0m $1.2m $6.9m $46.8m $37.6m $20.4m $22.3m $11.1m $33.8m ($32.2m)
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property ($9k) ($16k) ($397k) ($34k)
Gain (Loss) on Disposition of Property Plant Equipment ($44k) ($34k)
Cash, Cash Equivalents, and Short-term Investments $166.5m $386.4m $635.0m
Unrealized Gain (Loss) on Investments ($201k) ($620k) ($301k) $940k $78k $54k
Accretion of discounts and premiums on investments ($74k) $19k ($1.3m) ($3.4m) $1.9m $6.0m $474k ($3.6m) ($10.3m) ($7.2m)
Maturities of investments $120.7m $59.7m $41.0m $514.6m $676.6m $762.9m $522.7m $285.6m $428.0m $400.0m
Purchase of investments ($426.1m) ($417.7m) ($947.7m) ($725.2m) ($245.8m) ($205.9m) ($460.8m) ($318.7m) ($337.7m)
Net unrealized loss on investments ($201k) ($620k) ($301k) $940k $78k $54k
Payments to Acquire Businesses, Net of Cash Acquired $212.6m $0
Net Cash Provided by (Used in) Investing Activities $8.9m $58.7m ($386.3m) $90.0m ($317.9m) $132k $256.5m ($155.2m) ($96.4m) $47.5m ($44.9m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $1.0m
Proceeds from Issuance of Common Stock $95.7m $53.7m $398.8m $567.0m $203.2m $189.5m $463.3m $397.3m $306.3m $292.4m
Proceeds from the issuance of common stock under employee stock purchase plan $1.6m $1.7m $2.4m $3.0m $1.5m
Proceeds from the issuance of common stock upon exercise of options $626k $5.6m $10.0m $6.4m $9.7m $33.5m $1.6m $63k $3.3m $15k
Proceeds from the issuance of common stock, net $95.7m $53.7m $398.8m $567.0m $203.2m $189.5m $463.3m $397.3m $306.3m
Conversion of convertible preferred stock to common stock $3k $1k $1k $2k ($1k) $1k
Net Cash Provided by (Used in) Financing Activities $96.9m
$58.7m -39.44%
$424.3m +622.99%
$6.1m -98.56%
$576.4m +9301.76%
$239.3m -58.49%
$190.2m -20.53%
$463.0m +143.47%
$390.7m -15.62%
$300.8m -23.01%
$287.9m -4.30%
Net increase (decrease) in cash, cash equivalents and restricted cash $38.7m ($63.2m) ($62.7m) $53.4m $11.5m $153.8m ($56.8m) ($59.3m) $47.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $38.7m ($63.2m) ($62.7m) $53.4m $11.5m $153.8m ($56.8m) ($59.3m) $47.0m $117.2m
Cash, Cash Equivalents and Restricted Cash Beginning of Period $145.4m $82.2m $19.4m $72.9m $84.3m $238.2m $181.3m $122.1m $169.1m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.7m ($63.2m) $19.4m $72.9m $84.3m $238.2m $181.3m $122.1m $169.1m $117.2m
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ($2.7m) ($541k) $1.1m ($440k)
Effect of foreign exchange rate changes ($2.7m) ($541k) $1.1m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $626k $5.6m $10.0m $6.4m $9.7m $33.5m $1.6m $63k $3.3m $15k
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 $0 $0
Additional Financial Items
Foreign Currency Transaction Gain (Loss), before Tax ($70k) $175k $238k
Gain (Loss) on Termination of Lease $5.6m
Gain (Loss) Related to Litigation Settlement $336k
General and Administrative Expense $25.6m $21.3m $28.4m $40.8m $60.2m $83.7m $104.1m $106.9m $153.0m $152.3m
Investment Income, Interest $745k $813k $4.7m $9.3m $2.4m $451k $3.0m $13.0m $20.3m $10.3m
Operating Expenses $53.6m $92.9m $128.3m $206.9m $261.9m $342.7m $398.9m
Unrealized foreign exchange loss $70k ($175k) ($238k)
Loss on asset disposals $7.4m $44k
Operating lease liabilities ($6.1m) ($11.5m) ($5.9m) ($1.9m) ($10.8m) ($12.1m) ($10.9m)
Cash paid for acquisition, including contingent consideration, net of cash acquired ($212.6m) ($52.6m)
Tax payments related to shares withheld for vested restricted stock units ($642k) ($1.3m) ($223k) ($312k) ($284k) ($2.6m) ($2.8m) ($12.9m) ($7.1m)
Lease liabilities arising from obtaining right-of-use asset from new leases $14.8m $46.0m $17.3m $553k $177k $2.3m
Increase / (decrease) in lease liabilities due to obtaining/(reduction in) right-of-use assets from lease modifications $4.8m $826k $7.8m $15.3m $1.0m ($7.8m) $2.1m